Areas of Focus
- Drug Metabolism
- Adverse Drug Reaction Mechanisms
- New Metabolic Pathways
- Uncommon Pharmacokinetics
- New Drug Metabolism Technologies
- Low-Radiation Energy Radioisotope Labeling Techniques in New Drug DMPK
Work Experience
- 2019-02~Present - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Group Leader
- 2018-08~2019-02 - Celgene Corporation, USA - Scientist II
- 2016-06~2018-08 - XenoBiotic Laboratories, USA - Scientist I/II
- 2014-07~2016-06 - National Institutes of Health (NIH), USA - Postdoctoral Researcher
- 2009-09~2014-07 - University of Chinese Academy of Sciences - PhD Student
- 2005-09~2009-06 - Wuhan University - Bachelor's Student
Academic Background & Achievements
- 2009-09--2014-07 PhD: University of Chinese Academy of Sciences
- 2005-09--2009-06 Bachelor's: Wuhan University
Publications
- Pharmacokinetics, mass balance, and metabolism of [14C]TPN171, a novel PDE5 inhibitor, in humans for the treatment of pulmonary arterial hypertension, Xingxing Diao, 2022
- Mechanistic study on the species differences in excretion pathway of HR011303 in human and rats, Xingxing Diao, 2022
- Site-specific protein modification by 3-n-butylphthalide in primary hepatocytes: covalent protein adducts diminished by glutathione and N-acetylcysteine, Xingxing Diao, 2021
Awards
- 4th ISSX/CSSX Joint Meeting Second Prize (2013): Second Prize, Other
- 10th National Drug Analysis Excellent Paper Selection Third Prize (2011): Third Prize, Other
